Taylor Devices
TAYD
18 hedge funds and large institutions have $7.34M invested in Taylor Devices in 2019 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 1 reducing their positions, and 2 closing their positions.
600% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 1
0.25% more ownership
Funds ownership: 19.51% → 19.76% (+0.25%)
0% more funds holding
Funds holding: 18 → 18 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
11% less capital invested
Capital invested by funds: $8.25M → $7.34M (-$907K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Courier Capital
Buffalo,
New York
|
+$57.2K |
| 2 |
PCM
Perritt Capital Management
Chicago,
Illinois
|
+$25.7K |
| 3 |
Renaissance Technologies
New York
|
+$6.86K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.89K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$2.39K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$11 |
TAYD Hedge Fund Activity: Q2 2019 in Review
18 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Taylor Devices (TAYD) for Q2 2019, worth a combined $7.34M — down 11% from $8.25M a quarter earlier.
Fund positioning in TAYD was balanced in Q2 2019: 2 funds opened new positions, 2 closed out, 7 added to existing stakes and 1 trimmed.
The largest buyer was Courier Capital, adding an estimated $57.2K. The largest seller was Morgan Stanley, cutting an estimated $11.
- 18 institutional investors held Taylor Devices (TAYD) as of Q2 2019, unchanged from Q1 2019.
- Funds reported $7.34M of Taylor Devices stock for Q2 2019, down 11% quarter-over-quarter.
- 2 funds opened new Taylor Devices positions in Q2 2019 and 2 closed out, a net change of 0 holders.
- The largest Taylor Devices buyer in Q2 2019 was Courier Capital, an estimated $57.2K added.
- The largest Taylor Devices seller in Q2 2019 was Morgan Stanley, an estimated $11 sold.
Based on aggregated 13F filings for Q2 2019.